Adults with type 2 diabetes and obesity who started tirzepatide ↗ were about a quarter as likely to have a pulmonary embolism over the next year. The comparison group was near-identical patients who only changed their diet and exercise. A pulmonary embolism is a blood clot that breaks loose and lodges in the lungs. It is one of the more dangerous things that can happen to a heavy, sedentary patient. This is the largest look yet at whether the drug tracks with fewer of them.
The numbers come from a retrospective cohort study published July 1 in Frontiers in Endocrinology ↗. The authors pulled from the TriNetX US Collaborative Network, a pooled record of tens of millions of patients. They matched 117,600 people who started tirzepatide against the same number who took no weight-loss medication at all. Clots counted only if they showed up between one month and one year after the start date.
Over that window, tirzepatide users had roughly a quarter of the pulmonary embolism risk of the lifestyle-only group (relative risk 0.215, or about 79 percent lower; hazard ratio 0.258). Deep vein thrombosis, the leg-and-pelvis clots that often precede a lung clot, ran about a third as high (relative risk 0.303, hazard ratio 0.361). Superficial vein thrombosis, the milder near-surface kind, showed no clear difference. Both of the big reductions held up in a landmark analysis that ignored the first 90 days, which is the usual guard against crediting a drug for good outcomes in patients who were simply healthier to begin with.
What tirzepatide is, and why a clot signal is plausible
Tirzepatide, sold as Mounjaro and Zepbound, hits two gut-hormone receptors at once: GLP-1, the same one semaglutide ↗ engages, and GIP, its partner receptor. That dual action drives large weight loss and better blood sugar. There is a straightforward reason weight loss might cut clot risk. Obesity, poor glucose control, and inflammation all push blood toward clotting and keep patients less mobile. Take 15 or 20 percent of body weight off and several of those pressures ease at once. So a lower clot rate is a believable downstream effect, not a mystery.
The comparison that flatters the drug, and the one that does not
The catch is who ends up in each group. People a doctor puts on an expensive injectable are not a random draw. They tend to be more mobile, more engaged with care, and better able to tolerate a drug than people left on lifestyle advice alone. Some of the sickest patients are steered away from the medication entirely. That selection can manufacture a protective signal on its own, and a matched database study cannot fully erase it.
That is why the study's second comparison is the more honest test. When the authors put tirzepatide head to head against semaglutide, another GLP-1 drug given to a similar population, the deep vein thrombosis edge survived. The pulmonary embolism advantage held up only on the simpler risk-ratio math, and disappeared once time-to-event modeling was applied. The drug-versus-nothing gap is dramatic. The drug-versus-drug gap is smaller and, for lung clots, close to a wash.
That split is the useful sentence for anyone reading past the headline. Tirzepatide looks strongly clot-protective against doing nothing, and roughly even with its closest competitor. Both can be true, and only the second tells you much about the molecule.
The glucose-dependent insulinotropic polypeptide and GLP-1 receptors this drug works through anchor a large slice of the metabolic pipeline peptidemodel tracks, from single agonists like semaglutide to the dual and triple agents now in trials. A protective association on clotting, if it survives a proper prospective test, would be a point in favor of the whole GLP-1 receptor ↗ class, not tirzepatide alone. This study cannot deliver that verdict. It is a database association, not a trial, and it says nothing about cause. What it does is put a number on a question worth running a real trial to answer.